Cutaneous <i>Exophiala oligosperma</i> infection presenting with multiple, rosacea‐like papules on the cheek in a healthy individual

Demitsu, Toshio; Umemoto, Naoka; Maeda, Takeyasu; Kakurai, Maki; Harada, Kazutoshi

doi:10.1111/1346-8138.15418

Cited by 2 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, ravuconazole has high in vitro activity against Exophiala species 12 . Although only two patients infected by Exophiala species have been treated with fosravuconazole, 13 it remains a promising therapy for this disease. Terbinafine is an allylamine antifungal mainly used to treat dermatophyte infections, and the recommended regimen for toenail tinea unguium is 125 mg/day for 24 weeks in Japan.…”

Section: Discussionmentioning

confidence: 99%

Empiric antifungal therapy in patients with cutaneous and subcutaneous phaeohyphomycosis

Noguchi

Matsumoto

Kimura

et al. 2022

The Journal of Dermatology

View full text Add to dashboard Cite

We encountered two cases of phaeohyphomycosis caused by Exophiala jeanselmei and E. oligosperma that were treated with fosravuconazole and terbinafine, respectively. Our cases were successfully treated with empiric therapy before the pathogen’s species or antifungal sensitivity had been determined. We summarized 32 cases of cutaneous and subcutaneous phaeohyphomycosis caused by Exophiala species in Japan. The patients received antifungals, including itraconazole, terbinafine, voriconazole, and fosravuconazole, and the treatment success rates of these monotherapies were 77% (17/22), 67% (8/12), 100% (5/5), and 50% (1/2), respectively. Although the broad‐spectrum azole antifungal itraconazole is the first choice for treatment, terbinafine at 125 mg/day might exert the same efficacy. Fosravuconazole is a novel broad‐spectrum azole and a moderate inhibitor of Cyp3A4 that causes fewer drug interactions than itraconazole and voriconazole, indicating a promising drug for this disease.

show abstract

Section: Discussionmentioning

confidence: 99%